Show simple item record

dc.contributor.authorHawkes, E. A.
dc.contributor.authorPhillips, T.
dc.contributor.authorBudde, L. E.
dc.contributor.authorSantoro, A.
dc.contributor.authorSaba, N. S.
dc.contributor.authorRoncolato, F.
dc.contributor.authorGregory, G. P.
dc.contributor.authorVerhoef, G.
dc.contributor.authorOffner, F.
dc.contributor.authorQuero, C.
dc.contributor.authorRadford, John A
dc.contributor.authorGiannopoulos, K.
dc.contributor.authorStevens, D.
dc.contributor.authorThall, A.
dc.contributor.authorHuang, B.
dc.contributor.authorLaird, A. D.
dc.contributor.authorSandner, R.
dc.contributor.authorAnsell, S. M.
dc.date.accessioned2021-11-26T10:04:38Z
dc.date.available2021-11-26T10:04:38Z
dc.date.issued2021en
dc.identifier.citationHawkes EA, Phillips T, Budde LE, Santoro A, Saba NS, Roncolato F, et al. Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study [Internet]. Vol. 16, Targeted Oncology. Springer Science and Business Media LLC; 2021. p. 761–71.en
dc.identifier.pmid34687398en
dc.identifier.doi10.1007/s11523-021-00849-8en
dc.identifier.urihttp://hdl.handle.net/10541/624766
dc.description.abstractBackground: Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis despite the availability of multiple treatment options. Preliminary evidence suggests that DLBCL may be responsive to programmed death ligand 1 (PD-L1)/programmed death 1 inhibitors. Objective: The JAVELIN DLBCL study was conducted to assess whether a combination of agents could augment and sustain the antitumor immunity of avelumab, an anti-PD-L1 antibody, in R/R DLBCL. Methods: This was a multicenter, randomized, open-label, parallel-arm study with a phase Ib and a phase III component. Reported here are the results from the phase Ib study, wherein 29 adult patients with DLBCL were randomized 1:1:1 to receive avelumab in combination with utomilumab (an immunoglobulin G2 4-1BB agonist) and rituximab (arm A), avelumab in combination with utomilumab and azacitidine (arm B), or avelumab in combination with bendamustine and rituximab (arm C). The primary endpoints were dose-limiting toxicities and objective response as assessed by the investigator per Lugano Response Classification criteria. Results: Of the seven patients in arm A, one (14.3%) experienced two grade 3 dose-limiting toxicities (herpes zoster and ophthalmic herpes zoster); no dose-limiting toxicities were reported in arms B or C. No new safety concerns emerged for avelumab. One partial response was reported in arm A, three complete responses in arm C, and no responses in arm B. Given the insufficient antitumor activity in arms A and B and the infeasibility of expanding arm C, the study was discontinued before initiation of the phase III component. Conclusions: The low level of clinical activity suggests that PD-L1 inhibitor activity may be limited in R/R DLBCL. CLINICALTRIALS.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s11523-021-00849-8en
dc.titleAvelumab in combination regimens for relapsed/refractory DLBCL: results from the Phase Ib JAVELIN DLBCL studyen
dc.typeArticleen
dc.contributor.departmentOlivia Newton-John Cancer Research Institute, Austin Health, 145 Studley Road, Heidelberg, VIC, Australia.en
dc.identifier.journalTargeted Oncologyen
dc.description.noteen]
refterms.dateFOA2021-12-01T09:43:05Z


Files in this item

Thumbnail
Name:
34687398.pdf
Size:
1.168Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record